Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats (Q28373377)

2

0 references

Y Numaguchi

3

0 references

Y Toki

4

0 references

K Okumura

5

0 references

T Hayakawa

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

6

0 references

language of work or name

English

0 references

publication date

1999

0 references

published in

Life Sciences

0 references

volume

65

0 references

issue

12

0 references

page(s)

1265-74

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Anthracycline antibiotics in cancer therapy. Focus on drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Subcellular effects of adriamycin in the heart: a concise review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Combination therapy with probucol prevents adriamycin-induced cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Echocardiographic measurement of left ventricular mass and volume in normotensive and hypertensive rats. Necropsy validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Microsomal lipid peroxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

A simple fluorometric assay for lipoperoxide in blood plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Increased 1,2-diacylglycerol content in myopathic hamster hearts at a prenecrotic stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Carvedilol-liposome interaction: evidence for strong association with the hydrophobic region of the lipid bilayers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Cardiac adrenergic receptor effects of carvedilol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Alpha tocopherol improves focal glomerulosclerosis in rats with adriamycin-induced progressive renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8

Receptor pharmacology of carvedilol in the human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900362-8